For Investors

Be part of delivering a breakthrough in maternal & fetal medicine

©  2021 by Raydiant Oximetry, Inc.

Currently, there is no commercially available method to measure fetal oxygenation during birth. Our technology directly determines the fetal oxygen level using a safe, external, single-use sensor that integrates seamlessly into the current monitoring systems. It has the potential to become the standard of care for fetal monitoring during childbirth.

Raydiant Oximetry is poised to deliver a first-to-market commercial product to meet goals across all key stakeholders


Raydiant Oximetry is targeting an FDA indication that addresses 80% of annual births


Our technology received the coveted FDA Breakthrough designation and is protected by four families of patents.

Raydiant Oximetry technology is priced to offer attractive margins, while tucking into existing reimbursement codes.


The technology seamlessly integrates with FHR monitoring and does not interfere with existing hospital workflows.

Raydiant Oximetry has been funded by the NIH, NSF and private accredited investors.

NIH Logo.png
NSF Logo.png
Want to learn more about the investment opportunity? Contact us.